Trump signs executive actions to boost domestic drug manufacturing and oversight of gain-of-function research, raising concerns over potential higher costs and shortages.
Investors seek opportunities in small-cap and penny stocks globally, with varying financial profiles and prospects.
Rite Aid files for second bankruptcy in less than a year, citing vendor restrictions and lender withdrawal as key reasons.
Trump signs executive actions to boost domestic drug manufacturing and oversight of gain-of-function research, raising concerns over potential higher costs and shortages.
Investors seek opportunities in small-cap and penny stocks globally, with varying financial profiles and prospects.
Rite Aid files for second bankruptcy in less than a year, citing vendor restrictions and lender withdrawal as key reasons.
